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Background-—Older-generation anticonvulsants that highly induce cytochrome P450 enzyme system activity produce metabolic
abnormalities that may increase cardiovascular risk. The objective of this study was to evaluate the risk of ischemic
cerebrovascular and coronary events in adult new users of anticonvulsants that highly induce cytochrome P450 activity compared
with other anticonvulsant agents, as observed in a routine care setting.
Methods and Results-—This was a cohort study of patients 40 to 64 years old from the HealthCore Integrated Research Database
who had initiated an anticonvulsant medication between 2001 and 2006 and had no recorded major coronary or cerebrovascular
condition in the 6 months before treatment initiation. Propensity score (PS) matching was used to evaluate ischemic
cerebrovascular and coronary risk among anticonvulsant new users. High-dimensional propensity score (hdPS)–matched analyses
were used to conﬁrm adjusted ﬁndings. The study identiﬁed 913 events in 166 031 unmatched new treatment episodes with
anticonvulsant drugs. In a PS-matched population of 22 864 treatment episodes, the rate ratio (RR) for ischemic coronary or
cerebrovascular events associated with highly inducing agents versus other agents was 1.22 (95% CI, 0.90-1.65). The RR moved to
0.99 (95% CI, 0.73-1.33) with adjustment for hdPS matching (RR, 1.47; 95% CI, 0.95-2.28 for cerebrovascular events; RR, 0.70;
95% CI, 0.47-1.05 for coronary events).
Conclusions-—In this exploratory analysis, there was no evidence of a consistent and statistically signiﬁcant effect of initiating
anticonvulsants that highly induce cytochrome P450 activity on ischemic coronary or cerebrovascular outcomes compared with
other agents, given routine care utilization patterns. (J Am Heart Assoc. 2013;2:e000208 doi: 10.1161/JAHA.113.000208)
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A
nticonvulsant medications represent ﬁrst-line therapy
for patients with epilepsy or convulsions, but their use is
not limited to the control of seizures. Labeled indications
include bipolar disorder, neuropathic pain, and migraine
prophylaxis, and considerable off-label use has been repor-
ted.
1,2Given the heterogeneous prescribing patterns and
varied beneﬁts of anticonvulsant drugs, a clariﬁcation of their
safety proﬁle merits attention.
Several investigations have highlighted possible interac-
tions between anticonvulsant drugs and the cardiovascular
system. Some of the older anticonvulsants (ie, carbamaze-
pine, phenobarbital, phenytoin, and primidone) have been
associated with metabolic changes that may contribute to
cardiovascular risk. The mechanism underlying this associa-
tion might reside in the interaction between these medica-
tions and cytochrome P450 system activity.
3 Previous
investigations have shown that patients treated with anticon-
vulsants that highly induce cytochrome P450 enzyme system
activity, such as phenytoin, carbamazepine, or phenobarbital,
experienced elevated levels of total cholesterol and most of
the various lipid fractions, including low-density lipoprotein
(LDL) cholesterol and serum triglycerides,
3–5 as well as
increases in serum lipoprotein(a) (Lp[a]) and serum homocy-
steine.
6–9 Meaningful increases in total cholesterol, LDL
cholesterol, triglycerides, and Lp(a) have been observed after
2 to 3 months of therapy with carbamazepine,
6,10 and a
recent study found that switching from carbamazepine and
phenytoin to anticonvulsants not inducing cytochrome P450
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ORIGINAL RESEARCHenzyme system activity, such as lamotrigine and levetirace-
tam, decreased levels of serum cholesterol and C-reactive
protein after 6 weeks.
3 Studies have directly quantiﬁed
atherosclerotic changes associated with long-term therapy
with anticonvulsants
11 and have shown that carotid artery
intima-media thickness, a strong predictor for future vascular
events, appears to be positively correlated with the duration
of conventional anticonvulsant therapy.
12
In the current study we sought to evaluate the risk of
cardiovascular events associated with anticonvulsants that
highly induce cytochrome P450 activity compared with other
anticonvulsant agents as observed in routine care settings
among adult anticonvulsant new users. We also investigated
the risk of cardiovascular events associated with individual
anticonvulsant medications compared with a referent agent.
Methods
Study Population and Data Source
We conducted a cohort study of all subjects aged 40 to
64 years who ﬁlled a new prescription for an anticonvulsant
agent between July 1, 2001, and December 31, 2006 (index
date), and who had 6 months of continuous health plan
enrollment without use of any anticonvulsant preceding the
index date. Patients became members of the study cohort on
the day following the drug initiation. Exclusion criteria were
previously deﬁned (Figure 1).
13 Patients were also excluded if
they had experienced any ICD-9 diagnosis
14 of the following
events in the 6 months prior to the index date: acute
myocardial infarction, unstable angina, previous cardiac
procedures, and acute ischemic stroke (Table 1). The analy-
sis was restricted to new users of the study drugs to facilitate
the assessment of how hazards vary over time and to help
deﬁne the relationship between duration of use and level of
risk.
Medical and pharmacy data were collected from the
HealthCore Integrated Research Database, which contains
longitudinal healthcare claims data from commercial health
plans in the southeastern, mid-Atlantic, central, and western
regions of the United States. Data on medical care, prescrip-
tion drug use, and healthcare utilization are accessible for
each subject in the database. For this study, data were
available beginning in 2001 for 3 US states (Delaware,
Georgia, California), with data from 11 additional states
(Virginia, New York, New Jersey, Indiana, Kentucky, Missouri,
Ohio, Wisconsin, Connecticut, Maine, New Hampshire) begin-
ning in 2004. Information on the exact date and cause of
death was available for the entire study period through linking
with the National Death Index (NDI).
Personal identiﬁers were removed from the data set before
the analysis to protect subject conﬁdentiality. The study was
approved by the institutional review board of Brigham and
Women’s Hospital.
Anticonvulsant Medication Exposure
For study purposes, anticonvulsants were grouped into 2
categories: anticonvulsants that highly induce cytochrome
P450 enzyme system activity (ie, carbamazepine, phenobar-
bital, phenytoin, and primidone) and other anticonvulsants,
which included either those minimally inducing (ie, lamotri-
gine, oxcarbazepine, and topiramate) or those not inducing (ie,
gabapentin, levetiracetam, pregabalin, tiagabine, valproate,
and zonisamide) cytochrome P450 activity. Valproate, an
inhibitor of cytochrome P450 activity, was included among
the noninducing agents.
15,16
For our primary analysis, exposed participants were
initiators of any highly inducing anticonvulsant; unexposed
participants were initiators of any other anticonvulsant. To
investigate the risk associated with individual anticonvulsants,
we chose gabapentin and topiramate as our references; both
are not highly inducing agents that were among the most
widely used in our population during the study period and are
characterized by a wide range of indications.
Based on the medication prescribed on the index date,
each subject was identiﬁed as a new user of a speciﬁc
anticonvulsant category or agent. Follow-up began on the day
following the initial ﬁll. Patients were allowed to have gaps of
2,247,563 An convulsant prescrip ons ﬁlled
between July 1, 2001, and December 31, 2006
1,946,177 Excluded
Previously ﬁlled in prior 6 mo
Mul ple prescrip ons per pa ent on same
date
Filled by pa ents without con nuous health
plan enrollment in prior 6 mo
Filled by pa ents with hospitaliza ons ≥30 d
in prior 6 mo
3,766 Excluded
Filled by pa ents with ICD-9 code for cancer,
HIV, a empted suicide, or transplanta on in
prior 6 mo
Filled by pa ents with invalid days of drug
supply
Filled by pa ents younger than 15 years
297,620 Treatment episodes
301,386 An convulsant medica ons newly
prescribed between 7/1/01 and 12/31/06
166,031 Treatment episodes 40-64yr (for
150,124 pa ents) included in the study cohort
4,966 Excluded
Acute myocardial infarc on in prior 6 mo
Unstable angina in prior 6 mo
Previous cardiac procedures (either coronary
artery bypass gra  or percutaneous coronary
interven on) in prior 6 mo
Acute ischemic stroke in prior 6 mo
18 Excluded
Filled ethosuximide or felbamate in prior 6 mo
171,015 Treatment episodes 40-64 years
Figure 1. Flowchart of study cohort.
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Hup to 30 days between prescription ﬁll dates in the
calculation of continuous therapy. In the case of drug
discontinuation, the exposure risk window for each patient
treatment episode extended until 30 days after the expiration
of the supply of the last prescription. Participants were
followed until the end of their exposure risk window, switching
to another anticonvulsant agent, the occurrence of a study
event (the ﬁrst event occurring within each outcome category
investigated), death from causes not included in the study
outcome, end of continuous health plan enrollment, or the
end of the study period, whichever came ﬁrst (as-treated
analysis). Patients were allowed to contribute >1 treatment
episode if they had a 6-month washout period without ﬁlling
any study drug. In an alternative approach, assuming that any
cardiovascular event shortly after treatment start is unlikely to
be treatment emergent based on a metabolic hypothesis, we
required a 3-month induction period between the initial ﬁll and
the beginning of the follow-up time, limiting the analysis to
only those patients who were still receiving therapy at
3 months. Finally, to assess the impact of duration on
anticonvulsant therapy, we further limited the analysis to
patients who were continuously on therapy at 6 and
9 months, so follow-up started 6 and 9 months, respectively,
after the ﬁrst prescription was ﬁlled.
Outcomes
The primary study outcome was a composite of ischemic
coronary events (hospitalization for myocardial infarction,
acute coronary syndrome, cardiac revascularization proce-
dure, or death from ischemic heart disease) and ischemic
cerebrovascular events (ischemic stroke or ischemic cere-
brovascular death). For myocardial infarction, acute coronary
syndrome, cardiac revascularization procedure, and ischemic
stroke, we used previously validated claims algorithms
17–19
(Table 1). Ischemic cerebrovascular and coronary events
were also investigated as 2 separate outcome categories.
Causes of death were determined through NDI linkage.
Deaths from ischemic heart disease were identiﬁed through
recorded ICD-10 codes (I20-I25), whereas cerebrovascular
Table 1. Population Exclusion Criteria and Study Outcomes
Diagnosis/Procedure ICD-9CM ICD-10CM CPT-4 Comments
Exclusion Criteria
Acute myocardial
infarction
410.xx
Unstable angina/acute
coronary syndrome
411.xx
Previous cardiac
procedure (CABG+PCI)
00.66, 36.01, 36.02, 36.03, 36.04,
36.05, 36.06, 36.07, 36.09, 36.1x,
36.2x
33510 to 33536, 33545, 33572, 92973,
92980, 92981, 92982, 92984, 92995,
92996
Ischemic stroke 433.xx, 434.xx
Outcomes
Myocardial infarction 410.xy as primary or secondary,
y6¼23-day stay required (unless
patient died)
17
Acute coronary syndrome 411.xx as primary or secondary, 3-day
stay required (unless patient died)
18
Cardiac procedure
(CABG+PCI)
00.66, 36.01, 36.02, 36.03, 36.04,
36.05, 36.06, 36.07, 36.09, 36.1x,
36.2x
18
33510 to 33536, 33545, 33572, 92973,
92980, 92981, 92982, 92984, 92995,
92996
Ischemic stroke, without
transient ischemic
attack (TIA)
433.x1, 434.x1, 436.xx, 437.1x, or
437.9x
19
Death for ischemic heart
disease
I20.xx to I25.xx NDI primary
cause of
death
Cerebrovascular ischemic
death
I63.xx to I66.xx,
I67.2x, I67.8x,
167.9x
NDI primary
cause of
death
CPT-4, Current Procedural Terminology-4 codes; NDI, National Death Index; ICD, International Classiﬁcation of Diseases; CABG, coronary artery bypass grafting; PCI, percutaneous
coronary intervention.
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Hischemic deaths were identiﬁed as I63-I66, I67.2, I67.8, or
I67.9.
20 Only primary causes of death were considered.
Within each outcome category investigated, only the ﬁrst
event was considered. Patients were censored at this point
including any subsequent treatment episode(s).
Patient Characteristics
Patient characteristics were identiﬁed during the 6 months
preceding cohort entry and included age, sex, calendar year,
healthcare utilization, and comorbidities investigated via
ICD-9 codes and Current Procedural Terminology–4 (CPT-4)
codes.
21 These comorbidities included old myocardial infarc-
tion, stable angina, other ischemic heart diseases, hyperten-
sion, heart failure, arrhythmias, diabetes mellitus, transient
ischemic attack, other evidence of cerebrovascular disease
(cerebral hemorrhagic events, cerebrovascular procedure),
other cardiovascular conditions (eg, valvular disease, aneu-
rysm, or peripheral vascular disease), epilepsy and seizure
disorders, migraine, neuropathic pain, mood disorders, psy-
chotic disorders, dementia, and other psychiatric disorders.
Healthcare utilization included prior hospitalizations, physi-
cian visits, use of other cardiovascular and psychotropic
medications, and number of distinct medications used.
Statistical Analysis
Characteristics of the patients were cross-tabulated by their
use of anticonvulsant agents. For each exposure, the number
of treatment episodes, number of events, and incidence rates
for cardiovascular and cerebrovascular events were calculated
until the date of censoring.
To control for confounding by indication, we constructed
an exposure propensity score from the subjects’ baseline
covariates (Table 2).
22 Distinct propensity scores were esti-
mated for each comparison. Exposure groups were 1:1
matched on their propensity score (PS) using a “greedy”
matching algorithm
23 with a maximum caliper of 0.01.
Absolute standardized differences, that is, the difference in
means or proportions divided by the pooled standard
deviation, were used to compare covariates’ mean or
prevalence within exposure groups before and after PS
matching.
24 After PS matching, incidence rates, rate ratios
(RRs), and rate differences (RDs), with 95% conﬁdence
intervals (CIs), were calculated for each matched cohort for
all outcomes. To further improve covariate balance, we also
used high-dimensional propensity score (hdPS) matching,
which augmented the standard PS matching with 500 addi-
tional empirically identiﬁed covariates. The hdPS algorithm is
an automated technique that examines thousands of candi-
date covariates among different claims data dimensions in the
study population, for example, dispensed drugs, recorded
diagnoses, and performed procedures, and empirically prior-
itizes 500 potential confounders for matching (the detailed list
of the 500 empirical covariates included in the main analysis
is provided in the Supplemental Material). Some empirical
studies have shown that the hdPS algorithm may improve
adjustment for confounding.
25,26 Finally, to evaluate whether
the effect of highly inducing anticonvulsants versus other
anticonvulsants varied over time, we tested the proportional
hazards assumption by including an interaction term between
time and exposure in Cox proportional hazards regression
models.
Sensitivity analyses were performed to test the robustness
of the primary ﬁndings. First, we extended the exposure risk
window until 90 days after the expiration of the supply of the
last prescription, assuming that the atherogenic effect of
anticonvulsant therapy might persist longer after treatment
discontinuation. Second, mimicking an intention-to-treat
analysis, the initial exposure to a speciﬁc anticonvulsant
category or an individual agent was carried forward until the
end of a ﬁxed 2-year follow-up period.
Adjustments for multiple comparisons were not consid-
ered. In this exploratory analysis, we limited analyses to
estimation of effects and precision rather than any formal
statistical testing.
27,28
Results
We identiﬁed 166 031 new treatment episodes for 150 124
patients (Figure 1). Among those, 12 580 were new users of
highly inducing anticonvulsants and 153 451 were initiators
of other anticonvulsants. Compared with new users of other
agents, new users of highly inducing anticonvulsants were
more likely to be male, to have more frequent prior
hospitalizations, and to have a history of cardiac arrhythmia,
other cardiovascular diseases, hemorrhagic stroke, and
epilepsy (Table 2). Those patients visited a physician less
frequently, and were less likely to have a history of diabetes
and hyperlipidemia and to have received antihypertensives,
lipid-lowering agents, insulin, and oral hypoglycemics in the
6 months prior to anticonvulsant treatment initiation. These
covariates appeared to be balanced after PS matching. Within
the individual anticonvulsant medications, patients who were
gabapentin initiators were more likely to have a history of
stable angina or other ischemic coronary diseases and
patients with diabetes to have received antihypertensive
drugs, lipid-lowering agents, insulin, and oral hypoglycemic
drugs, whereas patients beginning topiramate were generally
younger and more likely to be female, to have a history of
migraine, and to have had fewer hospitalizations (Table 3).
The overall mean follow-up was 4.1 (5.4) months and was
compatible between exposure groups (4.6 and 4.1 months for
highly inducing anticonvulsants and other anticonvulsant
DOI: 10.1161/JAHA.113.000208 Journal of the American Heart Association 4
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HTable 2. Patient Characteristics by Drug Exposure in Original and PS-matched Populations for Highly Enzyme-Inducing
Anticonvulsants Versus Other Anticonvulsants*
†
Highly Inducing
Anticonvulsants (ACs) Other ACs
Absolute
Standardized
Difference
‡
Highly Inducing ACs
After PS Matching
Other ACs After
PS Matching
Absolute
Standardized
Difference After
PS Matching
Observations, No. n=12 580 n=15 3451 n=11 432 n=11 432
Age, y, mean (SD) 51.4 (7.0) 50.9 (6.8) 0.1 51.4 (7.0) 51.4 (7.0) 0.0
Female 6750 (53.7) 99969 (65.2) 0.2 6386 (55.9) 6378 (55.8) 0.0
Charlson index, score=0 9462 (75.2) 118365 (77.1) 0.0 8819 (77.1) 8812 (77.1) 0.0
Charlson index, score=1 1991 (15.8) 24536 (16.0) 0.0 1697 (14.8) 1736 (15.2) 0.0
Charlson index, score ≥2 1127 (9.0) 10550 (6.9) 0.1 916 (8.0) 884 (7.7) 0.0
N drugs, mean (SD) 5.7 (5.0) 7.4 (5.3) 0.3 5.9 (5.0) 5.9 (5.0) 0.0
Prior hospitalization 2783 (22.1) 18237 (11.9) 0.3 2126 (18.6) 2020 (17.7) 0.0
N visits, mean (SD) 2.9 (3.8) 4.2 (4.4) 0.3 3.1 (3.9) 3.2 (3.9) 0.0
Prior cardiovascular
hospitalization
1374 (10.9) 6504 (4.2) 0.3 956 (8.4) 886 (7.8) 0.0
History of myocardial infarction 39 (0.3) 382 (0.3) 0.0 33 (0.3) 43 (0.4) 0.0
Stable angina and other
ischemic coronary diseases
412 (3.3) 5310 (3.5) 0.0 372 (3.3) 380 (3.3) 0.0
Hypertension 2233 (17.8) 27659 (18.0) 0.0 1987 (17.4) 2007 (17.6) 0.0
Heart failure 137 (1.1) 1489 (1.0) 0.0 115 (1.0) 117 (1.0) 0.0
Cardiac arrhythmia 520 (4.1) 4399 (2.9) 0.1 409 (3.6) 442 (3.9) 0.0
Other cardiovascular diseases 418 (3.3) 3806 (2.5) 0.0 348 (3.0) 339 (3.0) 0.0
Hemorrhagic stroke 487 (3.9) 292 (0.2) 0.3 286 (2.5) 212 (1.9) 0.0
Transient ischemic attack (TIA) 177 (1.4) 984 (0.6) 0.1 131 (1.1) 160 (1.4) 0.0
Other ischemic cerebrovascular
disease
393 (3.1) 1587 (1.0) 0.1 288 (2.5) 288 (2.5) 0.0
Diabetes 1206 (9.6) 22278 (14.5) 0.2 1136 (9.9) 1231 (10.8) 0.0
Hyperlipidemia 911 (7.2) 13132 (8.6) 0.1 846 (7.4) 923 (8.1) 0.0
Peripheral vascular disease 140 (1.1) 719 (0.5) 0.1 111 (1.0) 88 (0.8) 0.0
Seizure disorder 2978 (23.7) 2802 (1.8) 0.7 1950 (17.1) 2052 (17.9) 0.0
Depression 1280 (10.2) 22692 (14.8) 0.1 1212 (10.6) 1166 (10.2) 0.0
Bipolar disorder 322 (2.6) 6912 (4.5) 0.1 319 (2.8) 359 (3.1) 0.0
Migraine 516 (4.1) 16358 (10.7) 0.3 506 (4.4) 552 (4.8) 0.0
Psychotic disorders 207 (1.7) 1419 (0.9) 0.1 159 (1.4) 199 (1.7) 0.0
Dementia 217 (1.7) 688 (0.5) 0.1 159 (1.4) 169 (1.5) 0.0
Alcohol/drug abuse 1125 (8.9) 7142 (4.7) 0.2 873 (7.6) 851 (7.4) 0.0
Any antihypertensive drug
§ 4606 (36.6) 60321 (39.3) 0.1 4250 (37.2) 4340 (38.0) 0.0
Lipid-lowering agents 2254 (17.9) 33108 (21.6) 0.1 2140 (18.7) 2148 (18.8) 0.0
Insulin 287 (2.3) 5521 (3.6) 0.1 272 (2.4) 292 (2.6) 0.0
Oral hypoglycemics 834 (6.6) 16023 (10.4) 0.1 790 (6.9) 861 (7.5) 0.0
Anticoagulants (heparin or
warfarin)
203 (1.6) 2607 (1.7) 0.0 190 (1.7) 188 (1.6) 0.0
Platelet-aggregation inhibitors
k 278 (2.2) 2893 (1.9) 0.0 248 (2.2) 220 (1.9) 0.0
Antiarrhythmic agents 58 (0.5) 524 (0.3) 0.0 52 (0.5) 44 (0.4) 0.0
Continued
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the PS-matched populations, respectively). Anticonvulsant
discontinuation (71.9%) and end of continuous plan enroll-
ment (18.5%) were the most common reasons for censoring.
During the follow-up period, we identiﬁed 913 ischemic
coronary or cerebrovascular events (611 coronary events and
328 cerebrovascular events), resulting in an event rate of 16.2
events per 1000 person-years (95% CI, 15.2-17.3). In a
PS-matched analysis, highly inducing anticonvulsants were
associated with a not statistically signiﬁcant increased risk of
ischemic coronary or cerebrovascular events compared with
the other anticonvulsant agents (RR, 1.22; 95% CI, 0.90-1.65;
Table 4).Thiseffectwasattenuatedto1.13(95%CI,0.70-1.82)
after accounting for a 3-month induction period. With adjust-
ment for 1:1 hdPS-matching, the RR moved to 0.99 (95% CI,
0.73-1.33),andto0.95(95%CI,0.59-1.52)afteraccountingfor
a 3-month induction period. However, when the 2 outcome
categories were considered separately, the hdPS analysis
suggested a nonsigniﬁcant increased risk of ischemic cerebro-
vascular events when highly inducing anticonvulsants were
compared with the other anticonvulsant agents (RR, 1.48; 95%
CI, 0.70-3.13). There was no indication of increased risk for
coronary events (RR, 0.75; 95% CI, 0.41-1.36). When duration
ontreatmentwasconsidered,theanalysissuggestedapossible
patternofincreasinghazardratiosforischemiccerebrovascular
events and for total cardiovascular risk (Table 5). However, the
testforproportionalitywasnotstatisticallysigniﬁcantforanyof
the 3 outcomes (P>0.05), which indicates that the effect of
highly inducing anticonvulsants versus other anticonvulsants
was not statistically different over time.
HdPS adjusted cumulative distribution function plots were
consistent with our ﬁndings (Figures 2–4).
The intention-to-treat-type analyses carrying forward the
ﬁrst exposure yielded results similar to the primary
“as-treated” analysis (Table 6). Similarly, there was no
meaningful difference when we extended the exposure risk
window until 90 days after drug discontinuation (Table 7).
In 1:1 hdPS-matched analyses of individual anticonvul-
sants, carbamazepine, primidone, oxcarbazepine, gabapentin,
and pregabalin initiators showed increased cardiovascular risk
when compared with topiramate (Figure 5). When compared
with gabapentin, the risk for these agents remained elevated
but became statistically nonsigniﬁcant. After accounting for a
3-month induction period, only carbamazepine and gabapen-
tin initiators appeared to have a statistically signiﬁcant
increased risk of cardiovascular events compared with
topiramate, with an RR of 3.51 (95% CI, 1.13-10.88) and an
RR of 2.06 (95% CI, 1.21-3.50), respectively. Carbamazepine
initiators consistently showed increased but not statistically
signiﬁcant risk when compared with gabapentin (RR, 2.0; 95%
CI, 0.82-4.91). The small subgroup sizes of individual
anticonvulsant agents did not allow for a conclusive investi-
gation of the separated outcomes.
Discussion
Anticonvulsant medications are widely prescribed for several
medical conditions, but little is known about their cardiovas-
cular safety. We evaluated ischemic cerebrovascular and
coronary risk in PS and hdPS–matched cohorts based on
166 031 anticonvulsant treatment episodes and 913 coro-
nary or cerebrovascular events.
We found no evidence of any consistent and meaningful
increase in the relative risk of ischemic coronary or cerebro-
vascular events associated with the use of anticonvulsants
that highly induce cytochrome P450 activity compared with
other agents during the study follow-up. However, we found a
not statistically signiﬁcant increase in the relative risk of
noticeable magnitude for cerebrovascular events, which
became more marked, although less precise, with duration
on treatment. In an evaluation of individual anticonvulsant
agents, the risk of ischemic coronary or cerebrovascular
events appeared to be consistently increased for initiators of
carbamazepine compared with topiramate or gabapentin.
Table 2. Continued
Highly Inducing
Anticonvulsants (ACs) Other ACs
Absolute
Standardized
Difference
‡
Highly Inducing ACs
After PS Matching
Other ACs After
PS Matching
Absolute
Standardized
Difference After
PS Matching
Observations, No. n=12 580 n=15 3451 n=11 432 n=11 432
Antidepressant agents 3761 (29.9) 72057 (47.0) 0.4 3631 (31.8) 3583 (31.3) 0.0
Antipsychotic agents 717 (5.7) 11115 (7.2) 0.1 682 (6.0) 717 (6.3) 0.0
SD indicates standard deviation; PS, propensity score; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker.
*The propensity scores were based on all the variables in Table 1 and calendar year.
†Six months prior to index date.
‡Absolute standardized difference was deﬁned as the difference in means divided by the pooled standard deviation.
26
§Includes angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, diuretics, calcium channel blockers, or other antihypertensives.
kIncludes clopidogrel, dipyridamole, aspirin/dipyridamole, or ticlopidine.
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HHowever, these latter results should be considered in light
of the small subgroup sizes of individual anticonvulsant
agents.
These ﬁndings are not incompatible with the hypothesis
that conventional anticonvulsants with highly inducing
cytochrome P450 enzyme system activity increase cardio-
vascular risk, possibly inﬂuencing atherothrombotic risk
factors such as serum lipids, lipoprotein(a), homocysteine,
and C-reactive protein and carotid artery intima-media
thickness and that the risk for cardiovascular events
increases with the duration of therapy. Our results of not
signiﬁcantly increased risk for cerebrovascular events but not
for coronary events may indicate different baseline risks in
the population. Epileptic seizures have been suggested to
be the ﬁrst manifestation of otherwise undiagnosed cerebro-
vascular disease.
29,30 In such a context, highly inducing
anticonvulsants might act as risk promoters and precipitate
the occurrence of cerebrovascular events.
Few investigations have directly addressed the relationship
between anticonvulsant medications and cardiovascular risk.
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Figure 2. Probability of ischemic coronary or cerebrovascular
events
a by anticonvulsant category and time since treatment
initiation.
ba Myocardial infarction, acute coronary syndrome, cardiac
revascularization procedure, death for ischemic heart disease,
ischemic stroke, or ischemic cerebrovascular death.
bAT, as-treated
analysis censoring at termination of exposure risk window, switching
to another anticonvulsant agent, occurrence of a study event, death
from causes not included in the study outcome, end of continuous
health plan enrollment, the end of the study period or end of 1 year,
whichever came ﬁrst.
cCumulative probability estimates of ischemic
coronary or cerebrovascular events over time were restricted to the
hdPS-matched sample. hdPS indicates high-dimensional propensity
score; ACs, anticonvulsants.
Table 5. Effect of Duration on Therapy with Highly Enzyme-Inducing Anticonvulsants Versus Other Anticonvulsants on Ischemic
Coronary* or Cerebrovascular
† Events in hdPS-Matched Population
‡
Duration on Anticonvulsant Therapy Ischemic Coronary or Cerebrovascular Events Ischemic Coronary Events Ischemic Cerebrovascular Events
HR (95%) HR (95%) HR (95%)
≥3 Months 0.98 (0.61 to 1.56) 0.77 (0.43 to 1.40) 1.47 (0.70 to 3.13)
≥6 Months 1.45 (0.75 to 2.82) 1.11 (0.48 to 2.53) 2.17 (0.77 to 6.11)
≥9 Months 1.81 (0.82 to 3.98) 1.17 (0.44 to 3.07) 4.81 (1.07 to 21.52)
Test for proportional hazards P=0.38 P=0.54 P=0.45
hdPS indicates high-dimensional propensity score; HR, hazard ratio.
*Myocardial infarction, acute coronary syndrome, cardiac revascularization procedure, or death for ischemic heart disease.
†Ischemic stroke or ischemic cerebrovascular death.
‡As-treated analysis censoring at termination of exposure risk window, switching to another anticonvulsant agent, occurrence of a study event, death from causes not included in the study
outcome, end of continuous health plan enrollment, or the end of the study period, whichever came ﬁrst.
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sant category and time since treatment initiation.
ba Myocardial
infarction, acute coronary syndrome, cardiac revascularization pro-
cedure, death for ischemic heart disease.
bAT, as-treated analysis
censoring at termination of exposure risk window, switching to
another anticonvulsant agent, occurrence of a study event, death
from causes not included in the study outcome, end of continuous
health plan enrollment, the end of the study period or end of 1 year,
whichever came ﬁrst.
cCumulative probability estimates of ischemic
coronary events over time were restricted to the hdPS-matched
sample. hdPS indicates high-dimensional propensity score; ACs,
anticonvulsants.
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HOlesen et al
31 found that patients with epilepsy being treated
with valproate had a lower risk of myocardial infarction
compared with the general population. The same authors
performed a cohort study of epileptic patients and found that,
compared with carbamazepine, both oxcarbazepine and
phenobarbital were associated with increased risk of cardio-
vascular death and all-cause death, oxcarbazepine with
increased risk of stroke, and valproate with a decreased risk
of MI and stroke.
32 Both those investigations did not address
a direct comparison between highly inducing anticonvulsants
and other agents, had different underlying populations, and
examined a restricted number of anticonvulsant agents.
Our study exhibits several strengths. Through the use of a
large claims-based population, we were able to investigate
new users of anticonvulsant drugs in a routine care setting.
Initiators of anticonvulsant drugs were compared with initia-
tors of an active referent anticonvulsant category or drug
(instead of no treatment) to provide clinicians with useful
information regarding the relative treatment risks and bene-
ﬁts. Finally, multiple approaches in the design and analysis of
the study were employed to minimize the potential for
residual confounding, including the restriction to drug initia-
tors without any major coronary or cerebrovascular events in
the 6 months prior to drug initiation, the restriction to
patients with at least 3 months of continuous anticonvulsant
therapy before follow-up started, and the extensive covariate
adjustment via standard PS- and hdPS–matched analyses.
There are limitations to be considered. Some important
characteristics might not have been completely captured as
either not fully or not directly measured in claims data, for
exaple, BMI, smoking, and disease severity. Although multiple
approaches in terms of study design and analysis were used,
including hdPS methodology, which has been shown to
improve adjustment by identifying covariates that may be
proxies for unmeasured characteristics,
25,26 residual con-
founding cannot be completely ruled out. Initiators of nonin-
ducing anticonvulsants, in particular gabapentin and
pregabalin, more frequently showed characteristics predictive
of higher cardiovascular risk. These characteristics, if not fully
measured in claims data and accounted for in the adjusted
analyses, may have contributed to the ﬁnding of not consistent
statistically signiﬁcant increases in the relative risk of ischemic
coronary or cerebrovascular events associated with the use of
highly inducing anticonvulsants compared with other agents.
Furthermore, pregabalin and gabapentin have been associated
with peripheral edema and weight gain,
33,34 possibly contrib-
uting to heart failure and left ventricular systolic dysfunction.
35
This might have diluted the effect on the cardiovascular
system of highly inducing anticonvulsants. A second limitation
is that anticonvulsant drug discontinuation or switching might
be related to early cardiovascular effects. This could have
made discontinuination or switching a predictor for cardiovas-
cular events that would not have been observed in an
as-treated analysis, therefore introducing bias toward the null.
To minimize this potential bias, we extended the exposure risk
window until 30 and 90 days after drug discontinuation, and
we also carried the ﬁrst exposure forward, similar to an
intention-to-treat analysis, without considering either drug
discontinuation or switching. The results of this analysis were
consistent. Another limitation is the high degree of drug
discontinuation in our routine care setting, which limited the
possibility of investigating the effect of anticonvulsant med-
ications beyond the ﬁrst 2 years of therapy with sufﬁcient
power. This reﬂects routine care, and the data are consistent
with real-world patterns of adherence. Regardless, meaningful
metabolic changes have been shown to occur as early as after
2 to 3 months of continuous treatment with highly inducing
anticonvulsants.
6,10
In conclusion, this study explores possible differences in
ischemic coronary or cerebrovascular risk among adult anti-
convulsant initiators in real-world healthcare settings. There
wasnoevidenceofaconsistentstatisticallysigniﬁcantincrease
in the relative risk of ischemic coronary or cerebrovascular
events associated with the use of anticonvulsants that highly
induce cytochrome P450 activity compared with other agents.
However, the numerical increase in cerebrovascular risk
supportsthepossibilityofamodestclinicaleffectintheroutine
care of adult patients that may increase with duration on
therapy.
Adjusted Analysis for 1:1 hdPSmatching
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